

***謝佳訓醫師**

所有發表期刊論文及演講

1. **Chia-Hsun Hsieh**, John WC Chang, Jia-Juan Hsieh, Todd Hsu, Shiu-Feng Huang, Chun-Ta Liao, Hung-Ming Wang. Epidermal Growth Factor Receptor Mutations in Patients with Oral Cavity Cancer in a Betel Nut Chewing-Prevalent Area. Head & Neck, 2011, Epub, in press. DOI: 10.1002/hed.21665
2. John Wen-Cheng Chang, Nien-Chih Wei, Hung-Ju Su, Jie-Len Huang, Tse-Ching Chen, Yi-Cheng Wu, Chih-Teng Yu, Ming-Mo Hou, **Chia-Hsun Hsieh**, Jia-Juan Hsieh, Chiao-En Wu, Hsin-Yi Cheng, Todd Hsu and Tzu-Hao Wang*. Comparison of Genomic Signatures of Non-small Cell Lung Cancer Recurrence between Two Microarray Platforms. Anticancer Research. Volume 32, Issue No. 4, 2012
3. Po-Jung Su, **Chia-Hsun Hsieh**, Tsai-Sheng Yang. Leptomeningeal carcinomatosis from a Primary Colon Cancer Patient. J. Cancer Res. Pract. 27(3), 113-116, 2011.
4. **Chia-Hsun Hsieh**, Po-Jung Su, Chien-An Hsieh, Chia-Hung Yang, Chaung-Chi Liaw. ST-segment Elevation Acute Myocardial Infarction after 5-fluorouracil infusion: one case report and literature review. J. Cancer Res. Pract. 28(1), 28-34, 2012.
5. **Chia-Hsun Hsieh**, Cheng-lung Hsu, Cheng-Hsu Wang, Chaung-Chi Liaw, Jen-Shi Chen, Hsien-Kun Chang, Tsai-Shen Yang, John Wen-Cheng Chang; Yun12317ng-Chang Lin; Chi-Ting Liao, Ngan-Ming Tsang, Joseph Tung-Chieh Chang, Shu-Hang Ng, *Hung-Ming Wang. Cisplatin, Tegafur-Uracil (UFUR) and Leucovorin Plus Mitomycin C as an Outpatient Regimen for Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Trial. (Accepted by Chang Gung Medical Journal, ahead for print, 2012)
6. Cheng, W. H., Kao, C. Y., Hung, Y. S., Su, P. J., **Hsieh, C. H.**, Chen, J. S., Wang, H. M., Chou, W. C. (2012). Validation of a palliative prognostic index to predict life expectancy for terminally ill cancer patients in a hospice consultation setting in Taiwan. Asian Pac J Cancer Prev. 13(6): 2861-2866.
7. Shih-Siou Wang, Song-Bin Huang, **Chia-Hsun Hsieh**, Yung Chang Lin, Chao-Sung Lai, Min-Hsien Wu. An integrated microfluidic cell culture system for high-throughput perfusion three-dimensional cell culture-based assays: Effect of cell culture model on the results of chemosensitivity assays. (Accepted by Lab-on-A-Chip in 2012, ahead of print. SCI Impact factor: 5.670 BIOCHEMICAL RESEARCH METHODS: 6/72)
8. Song-Bin Huang, Min-Hsien Wu, Yen-Heng Lin, **Chia-Hsun Hsieh**, Chih-Liang Yang, Hung-Chih Lin, Ching-Ping Tseng and Gwo-Bin Lee. High-purity and label-free isolation of circulating tumor cells (CTCs) after conventional negative selection-based CTC isolation process in a microfluidic platform by using

optically-induced-dielectrophoretic (ODEP) force. (Accepted by Lab-on-A-Chip in 2012, ahead of print. SCI Impact factor: 5.670 BIOCHEMICAL RESEARCH METHODS: 6/72)

9. **Chia-Hsun Hsieh**, Hung-Chih Lin, Hung-Chih Hsu, Hung-Ming Wang, Chi-Ya Huang, Min-Hsien Wu and Ching-Ping Tseng. A negative selection system PowerMag for enhanced detection of EpCAM positive and negative circulating tumor cells: implication in disease progression monitoring. (Accepted by CLINICA CHIMICA ACTA, 2012, ahead of print.)
10. Cheng, W. H., Kao, C. Y., Hung, Y. S., Su, P. J., **Hsieh, C. H.**, Chen, J. S., Wang, H. M., *Chou, W. C. (2012). "Validation of a palliative prognostic index to predict life expectancy for terminally ill cancer patients in a hospice consultation setting in Taiwan." Asian Pac J Cancer Prev **13**(6): 2861-2866.
11. Characteristics of patients with hematologic malignancies who received palliative care consultation services in a medical center" in its current form for publication in the American Journal of Hospice and Palliative Medicine. (In submission)
12. Longitudinal Changes and Predictors of Caregiving Burden While Providing End-of-Life Care for Terminally Ill Cancer Patients. (In submission)

ABSTRACTS

1. **Chia-Hsun Hsieh**, John WC Chang, Jia-Juan Hsieh, Todd Hsu, Shiu-Feng Huang, Chun-Ta Liao, Hung-Ming Wang. Identification of Epidermal Growth Factor Receptor Mutations in Patients with Head and Neck Squamous Cell Carcinoma. **Annual Meeting of Taiwan Society of Internal Medicine. 2009.**
2. **Chia-Hsun Hsieh**, Yung-Chang Lin, Chaung-Chi Liaw, Rong-Nan Ching, Cheng-Hsu Wang, Jen-Shi Chen. Octreotide Long-acting Release for Patients with Functional Gastroenteropancreatic Neuroendocrine Tumors - An Experience in Chang Gung Memorial Hospital. . **The 15th Taiwan Joint Cancer Conference, 2010.**
2. **Chia-Hsun Hsieh**, Chia-Hsun Hsieh, Wen-Chi Chou, Yung-Chang Lin, Chaung-Chi Liaw, Rong-Nan Chien, Cheng-Hsu Wang, Hung-Chih Hsu, Jen-Shi Chen. Octreotide Long-acting Release Therapy for Patients with Functioning and Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Retrospective Analysis in Chang-Gung Memorial Hospital. **The 9th European Neuroendocrine Tumor Conference Meeting in Denmark, 2012.**
3. **Chia-Hsun Hsieh**, Cheng-lung Hsu, Cheng-Hsu Wang, Chaung-Chi Liaw, Jen-Shi Chen, Hsien-Kun Chang, Tsai-Shen Yang, John Wen-Cheng Chang; Yung-Chang Lin; Chi-Ting Liao, Ngan-Ming Tsang, Joseph Tung-Chieh Chang, Shu-Hang Ng, Hung-Ming Wang. Cisplatin, Tegafur-Uracil (UFUR) and Leucovorin Plus Mitomycin C as an Outpatient Regimen for Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Trial. **The 16th Taiwan Joint Cancer**

Conference, 2011. & 21th Asia Pacific Cancer Conference, 2011 in Malaysia

4. **Chia-Hsun Hsieh**, Cheng-Lung Hsu, Tung-Chieh Joseph Chang, Chien-Yu Lin, Kang-Hsing Fan, Shiang-Fu Huang, Hung-Jan Kang, Chun-Ta Liao, I-How Chen, Hung-Ming Wang. Chemoradiotherapy with Cisplatin, Tegafur-uracil plus Leucovorin for Patients with Locally Advanced Nasopharyngeal Carcinoma: A Phase II Trial **(2012 17th Taiwan Joint Cancer Conference, Accepted as Good Article Award)**
5. **Chia-Hsun Hsieh**, Cheng-Lung Hsu, Tung-Chieh Joseph Chang, Chien-Yu Lin, Kang-Hsing Fan, Shiang-Fu Huang, Hung-Jan Kang, Chun-Ta Liao, I-How Chen, Hung-Ming Wang. Outcome analysis of high risky oral cavity squamous cell carcinoma treated with surgery plus adjuvant chemoradiotherapy with cisplatin 100 mg/m² every 3week. **(2012 17th Taiwan Joint Cancer Conference)**
6. **Chia-Hsun Hsieh**, Cheng-Lung Hsu, Tung-Chieh Joseph Chang, Chien-Yu Lin, Kang-Hsing Fan, Shiang-Fu Huang, Hung-Jan Kang, Chun-Ta Liao, I-How Chen, Hung-Ming Wang. Preliminary Report of Neoadjuvant Chemotherapy of Docetaxel/Cisplatin/5-fluorouracil (TPF) in Unresectable Head & Neck Squamous Cell Carcinoma. **(2012 17th Taiwan Joint Cancer Conference)**
7. Sanger Hung-Chih Lin, Min-Hsien Wu, Hung-Chih Hsu, **Chia-Hsun Hsieh**, Ju-Chien Cheng, Ching-Ping Tseng. A new approach to isolate label-free and viable circulating tumor cells for monitoring cancer patient treatment response. **(2012 AACR Abstract #2383)**
8. Sanger Hung-Chih Lin, **Chia-Hsun Hsieh**, Ching-Ping Tseng. A new approach to isolate label-free and viable circulating tumor cells for monitoring cancer patient treatment response. **(2013 CellTech, in San Diego Abstract, Best Abstract Award)**

ORAL PRESENTATION in International Conference

1. **Chia-Hsun Hsieh**, Cheng-lung Hsu, Cheng-Hsu Wang, Chaung-Chi Liaw, Jen-Shi Chen, Hsien-Kun Chang, Tsai-Shen Yang, John Wen-Cheng Chang; Yung-Chang Lin; Chi-Ting Liao, Ngan-Ming Tsang, Joseph Tung-Chieh Chang, Shu-Hang Ng, Hung-Ming Wang. Cisplatin, Tegafur-Uracil and Leucovorin Plus Mitomycin C as an Outpatient Regimen for Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Trial. **(SEMBA conference, 2012, Taichung, Taiwan)**
2. **Chia-Hsun Hsieh**, Cheng-Lung Hsu, Tung-Chieh Joseph Chang, Chien-Yu Lin, Kang-Hsing Fan, Shiang-Fu Huang, Hung-Jan Kang, Chun-Ta Liao, I-How Chen, Hung-Ming Wang. Chemoradiotherapy with Cisplatin, Tegafur-uracil plus Leucovorin for Patients with Locally Advanced Nasopharyngeal Carcinoma: A Phase II Trial **(2012 17th Taiwan Joint Cancer Conference, Accepted as Good**

Poster Award)

3. **Jason, Chia-Hsun Hsieh**, Yung-Chang Lin. A Randomized Controlled, Double-blind Phase II Trial of BKM120 plus Metformin Concomitantly with First-line Paclitaxel Therapy versus Metformin plus Paclitaxel in Non-diabetic Patients with HER-2-negative, Locally advanced or Metastatic Breast Cancer. **(2012 1st MD Anderson J-HOPE Program, Tokyo, Japan)**